Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever.
OBJECTIVE
Empirical use of intravenous (IV) itraconazole (ITZ) for febrile neutropenic patients has recently been introduced in Korea. This study was designed to investigate the population pharmacokinetics (PK) of IV-ITZ.


METHODS
Sparse PK data were collected from febrile neutropenic patients undergoing empirical ITZ therapy at 200 mg/day after loading doses. NONMEM (Version. 5.1.1) was used to estimate population PK parameters.


RESULTS
Forty-two patients were enrolled in the study. Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively. Body weight was the only contributing covariate of CL. The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL.


CONCLUSIONS
In this study, we explored the population PK profile of ITZ given in IV formulation. We found that the current dosage regimen of IV-ITZ (200 mg/day) was appropriate to obtain therapeutic trough concentrations for neutropenic patients in Korea.
Lee
D-G
DG
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Korea.
Chae
H
H
Yim
Dong-Seok
DS
Park
S H
SH
Choi
S-M
SM
Kim
S
S
Choi
J-H
JH
Yoo
J-H
JH
Shin
W-S
WS
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001835:Body Weight; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D017964:Itraconazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007723:Korea; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology; D017711:Nonlinear Dynamics; D011446:Prospective Studies; D055815:Young Adult
D000935:Antifungal Agents; D017964:Itraconazole